Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
Dr Jabbour discussed recent phase 3 PhALLCON trial (NCT03589326) data, supporting more potent third-generation tyrosine kinase inhibitor (TKI) ponatinib’s move to the frontline for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Adding ponatinib up front doubled minimal residual disease negativity complete response rates vs standard second-generation TKIs, meeting the primary end point. More patients avoided transplant, with improved event-free survival. Manageable cardiovascular risk was shown with dose adjustment. Dr McCloskey addressed challenges in Ph+ ALL and said selecting optimal TKI therapy is still based on patient factors, but ponatinib’s early activity and favorable safety support its use earlier in therapy to improve outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More